252 related articles for article (PubMed ID: 23849326)
1. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens PL; Cloyd JC; Kriel RL; Remmel RP
Clin Drug Investig; 2007; 27(4):243-50. PubMed ID: 17358096
[TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of oxcarbazepine oral suspension vs. film-coated tablet in healthy Chinese male subjects.
Souppart C; Yin Q; Merz M; Hu P; Jiang J; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):538-44. PubMed ID: 18826868
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
11. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
12. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
13. Oxcarbazepine in infants and young children with partial seizures.
Northam RS; Hernandez AW; Litzinger MJ; Minecan DN; Glauser TA; Mangat S; Zheng C; Souppart C; Sturm Y
Pediatr Neurol; 2005 Nov; 33(5):337-44. PubMed ID: 16243221
[TBL] [Abstract][Full Text] [Related]
14. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
Keränen T; Sorri A; Moilanen E; Ylitalo P
Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
[TBL] [Abstract][Full Text] [Related]
15. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites.
Mogensen PH; Jórgensen L; Boas J; Dam M; Vesterager A; Flesch G; Jensen PK
Acta Neurol Scand; 1992 Jan; 85(1):14-7. PubMed ID: 1546529
[TBL] [Abstract][Full Text] [Related]
16. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.
Theis JG; Sidhu J; Palmer J; Job S; Bullman J; Ascher J
Neuropsychopharmacology; 2005 Dec; 30(12):2269-74. PubMed ID: 16052246
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
18. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
20. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]